Plasma-protein companies are unhappy about having to pay the ObamaCare pharmaceutical fee: http://finance.yahoo.com/news/IRS-Proposed-Regulations-on-prnews-4238685858.html?x=0&.v=1 The fee is waived for products with an FDA Orphan Drug designation, but most plasma-protein products don’t qualify for such a designation.